Lava Therapeutics N.V. (LVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -19,306 | -12,118 | -3,479 | -25,114 | -21,237 |
| Depreciation Amortization | 118 | -992 | -456 | -2,169 | -1,655 |
| Income taxes - deferred | N/A | N/A | N/A | -10 | N/A |
| Accounts payable and accrued liabilities | -1,264 | -1,465 | -1,246 | -1,569 | -2,662 |
| Other Working Capital | -8,816 | -8,616 | -3,638 | 4,383 | 228 |
| Other Operating Activity | -994 | -2,203 | -2,826 | 4,935 | 6,276 |
| Operating Cash Flow | $-30,262 | $-25,394 | $-11,645 | $-19,544 | $-19,050 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 288 | 283 | N/A | 65 | 66 |
| Purchase Of Investment | N/A | -34,621 | -4,947 | -97,090 | -75,567 |
| Sale Of Investment | 40,076 | 47,000 | 20,106 | 109,500 | 77,000 |
| Investing Cash Flow | $40,364 | $12,662 | $15,159 | $12,475 | $1,499 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | N/A | 27 | 25 |
| Other Financing Activity | 0 | 0 | 0 | -596 | 0 |
| Financing Cash Flow | $N/A | $N/A | $N/A | $-569 | $25 |
| Exchange Rate Effect | 4,547 | 4,097 | 1,145 | -1,578 | 261 |
| Beginning Cash Position | 35,015 | 35,015 | 35,015 | 44,231 | 44,231 |
| End Cash Position | 49,664 | 26,380 | 39,674 | 35,015 | 26,966 |
| Net Cash Flow | $14,649 | $-8,635 | $4,659 | $-9,216 | $-17,265 |
| Free Cash Flow | |||||
| Operating Cash Flow | -30,262 | -25,394 | -11,645 | -19,544 | -19,050 |
| Capital Expenditure | N/A | 283 | N/A | -23 | -23 |
| Free Cash Flow | -30,262 | -25,111 | -11,645 | -19,567 | -19,073 |